190 related articles for article (PubMed ID: 11520209)
1. Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.
Carceller E; Salas J; Merlos M; Giral M; Ferrando R; Escamilla I; Ramis J; García-Rafanell J; Forn J
J Med Chem; 2001 Aug; 44(18):3001-13. PubMed ID: 11520209
[TBL] [Abstract][Full Text] [Related]
2. Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat.
Gálvez J; Garrido M; Merlos M; Torres MI; Zarzuelo A
Br J Pharmacol; 2000 Aug; 130(8):1949-59. PubMed ID: 10952687
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J
J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517
[TBL] [Abstract][Full Text] [Related]
4. 5-Aminosalicylic Acid Azo-Linked to Procainamide Acts as an Anticolitic Mutual Prodrug via Additive Inhibition of Nuclear Factor kappaB.
Kim W; Nam J; Lee S; Jeong S; Jung Y
Mol Pharm; 2016 Jun; 13(6):2126-35. PubMed ID: 27112518
[TBL] [Abstract][Full Text] [Related]
5. The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production.
Gálvez J; Garrido M; Rodríguez-Cabezas ME; Ramis I; de Medina FS; Merlos M; Zarzuelo A
Inflamm Bowel Dis; 2003 Nov; 9(6):363-71. PubMed ID: 14671485
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis.
Jilani JA; Shomaf M; Alzoubi KH
Drug Des Devel Ther; 2013; 7():691-8. PubMed ID: 23983456
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
[TBL] [Abstract][Full Text] [Related]
8. Using Theory To Extend the Scope of Azobenzene Drugs in Chemotherapy: Novel Combinations for a Specific Delivery.
Cerón-Carrasco JP; Jacquemin D
ChemMedChem; 2021 Jun; 16(11):1764-1774. PubMed ID: 33619857
[TBL] [Abstract][Full Text] [Related]
9. Colon-specific prodrugs of 5-aminosalicylic acid: synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid.
Jung YJ; Lee JS; Kim YM
J Pharm Sci; 2001 Nov; 90(11):1767-75. PubMed ID: 11745734
[TBL] [Abstract][Full Text] [Related]
10. The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis.
Camuesco D; Rodríguez-Cabezas ME; Garrido-Mesa N; Cueto-Sola M; Bailón E; Comalada M; Arribas B; Merlos M; Balsa D; Zarzuelo A; Janer G; Xaus J; Román J; Gálvez J
Br J Pharmacol; 2012 Feb; 165(3):729-40. PubMed ID: 21790535
[TBL] [Abstract][Full Text] [Related]
11. Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan: synthesis, kinetic studies and evaluation of its mitigating effect in trinitrobenzenesulfonic acid-induced colitis in rats.
Dhaneshwar SS; Gairola N; Kandpal M; Vadnerkar G; Bhatt L
Bioorg Med Chem; 2007 Jul; 15(14):4903-9. PubMed ID: 17499512
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
Dhaneshwar SS; Kandpal M; Vadnerkar G; Rathi B; Kadam SS
Eur J Med Chem; 2007 Jun; 42(6):885-90. PubMed ID: 17258353
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of mutual azo prodrugs of anti-inflammatory agents and peptides facilitated by α-aminoisobutyric acid.
Kennedy DA; Vembu N; Fronczek FR; Devocelle M
J Org Chem; 2011 Dec; 76(23):9641-7. PubMed ID: 22026631
[TBL] [Abstract][Full Text] [Related]
14. A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model.
Yang Y; Kim W; Kim D; Jeong S; Yoo JW; Jung Y
Drug Des Devel Ther; 2019; 13():231-242. PubMed ID: 30643389
[TBL] [Abstract][Full Text] [Related]
15. Design and development of novel azo prodrugs using various permutations and combinations of 5- and 4-aminosalicylic acids for inflammatory bowel disease: a colon-targeted approach.
Suneela D; Gaurav V; Himanshu R
Inflamm Allergy Drug Targets; 2013 Oct; 12(5):328-40. PubMed ID: 24001333
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model.
Sawarkar SP; Deshpande SG; Bajaj AN; Nikam VS
AAPS PharmSciTech; 2015 Dec; 16(6):1445-54. PubMed ID: 26017284
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
Li F; Wu G; Zheng H; Wang L; Zhao Z
Eur J Med Chem; 2016 Jan; 108():486-494. PubMed ID: 26717200
[TBL] [Abstract][Full Text] [Related]
18. Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
Fray MJ; Bull DJ; Cooper K; Parry MJ; Stefaniak MH
J Med Chem; 1995 Sep; 38(18):3524-35. PubMed ID: 7658439
[TBL] [Abstract][Full Text] [Related]
19. Novel antagonists of platelet-activating factor. 1. Synthesis and structure-activity relationships of benzodiazepine and benzazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
Fray MJ; Cooper K; Parry MJ; Richardson K; Steele J
J Med Chem; 1995 Sep; 38(18):3514-23. PubMed ID: 7658438
[TBL] [Abstract][Full Text] [Related]
20. 5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity.
Jeong S; Lee H; Kim S; Ju S; Kim W; Cho H; Kim HY; Heo G; Im E; Yoo JW; Yoon IS; Jung Y
Mol Pharm; 2020 Jan; 17(1):167-179. PubMed ID: 31743034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
